Skip to main content
NCBI home page
Canadian Medical Association Journal logoLink to Canadian Medical Association Journal
. 1984 Sep 15;131(6):601–603.

Propafenone for the treatment of severe ventricular arrhythmias.

S W Rabkin, C E Rotem, K Boroomand-Rashti, B Bar-Shlomo
PMCID: PMC1483644  PMID: 6478345

Abstract

Twenty-one patients whose severe ventricular arrhythmias were not controlled by other currently used antiarrhythmic agents or who were intolerant of those drugs were treated with a new antiarrhythmic agent, propafenone. This therapy was associated with complete or nearly complete suppression of premature ventricular beats in 15 (71%) of the patients, satisfactory control in 4 (19%) and no control in 2 (10%). The majority reported no adverse effects. The most frequent complaints were nausea or epigastric discomfort (in five patients) and lightheadedness or dizziness (in three patients). Thus, propafenone appeared to be an effective antiarrhythmic agent with an acceptable frequency of side effects when administered to patients whose ventricular arrhythmias were difficult to treat.

Full text

PDF
601

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beck O. A. Propafenon, ein neues Antiarrhythmikum zur Therapie tachykarder und extrasystolischer Herzrhythmusstörungen. Med Klin. 1975 Jan 17;70(3-2):95–101. [PubMed] [Google Scholar]
  2. Beck O. A., Vogt J., Hochrein H. Der Einfluss von Antiarrhythmika auf die Hämodynamik bei akutem Myokardinfarkt (Vergleich von Propafenon mit Lidocain). Z Kardiol. 1978 Jan;67(1):41–45. [PubMed] [Google Scholar]
  3. Connolly S. J., Kates R. E., Lebsack C. S., Harrison D. C., Winkle R. A. Clinical pharmacology of propafenone. Circulation. 1983 Sep;68(3):589–596. doi: 10.1161/01.cir.68.3.589. [DOI] [PubMed] [Google Scholar]
  4. Jungowska-Klin B., Lozińska M., Wojtaszek J. The effect of X-irradiation on the alanine--and aspartate aminotransferase activity in the liver, kidney and spleen of mouse. Acta Physiol Pol. 1975 Jan-Feb;26(1):95–101. [PubMed] [Google Scholar]
  5. Karagueuzian H. S., Fujimoto T., Katoh T., Peter T., McCullen A., Mandel W. J. Suppression of ventricular arrhythmias by propafenone, a new antiarrhythmic agent, during acute myocardial infarction in the conscious dog. A comparative study with lidocaine. Circulation. 1982 Dec;66(6):1190–1198. doi: 10.1161/01.cir.66.6.1190. [DOI] [PubMed] [Google Scholar]
  6. Keller K., Meyer-Estorf G., Beck O. A., Hochrein H. Correlation between serum concentration and pharmacological effect on atrioventricular conduction time of the antiarrhythmic drug propafenone. Eur J Clin Pharmacol. 1978 Mar 17;13(1):17–20. doi: 10.1007/BF00606676. [DOI] [PubMed] [Google Scholar]
  7. Kohlhardt M., Seifert C. Inhibition of Vmax of the action potential by propafenone and its voltage-, time- and pH-dependence in mammalian ventricular myocardium. Naunyn Schmiedebergs Arch Pharmacol. 1980;315(1):55–62. doi: 10.1007/BF00504230. [DOI] [PubMed] [Google Scholar]
  8. Kotler M. N., Tabatznik B., Mower M. M., Tominaga S. Prognostic significance of ventricular ectopic beats with respect to sudden death in the late postinfarction period. Circulation. 1973 May;47(5):959–966. doi: 10.1161/01.cir.47.5.959. [DOI] [PubMed] [Google Scholar]
  9. Ledda F., Mantelli L., Manzini S., Amerini S., Mugelli A. Electrophysiological and antiarrhythmic properties of propafenon in isolated cardiac preparations. J Cardiovasc Pharmacol. 1981 Nov-Dec;3(6):1162–1173. doi: 10.1097/00005344-198111000-00002. [DOI] [PubMed] [Google Scholar]
  10. Moss A. J., DeCamilla J., Engstrom F., Hoffman W., Odoroff C., Davis H. The posthospital phase of myocardial infarction: identification of patients with increased mortality risk. Circulation. 1974 Mar;49(3):460–466. doi: 10.1161/01.cir.49.3.460. [DOI] [PubMed] [Google Scholar]
  11. Rabkin S. W., Mathewson F. A., Tate R. B. Relationship of ventricular ectopy in men without apparent heart disease to occurrence of ischemic heart disease and sudden death. Am Heart J. 1981 Feb;101(2):135–142. doi: 10.1016/0002-8703(81)90655-4. [DOI] [PubMed] [Google Scholar]
  12. Ruberman W., Weinblatt E., Goldberg J. D., Frank C. W., Shapiro S. Ventricular premature beats and mortality after myocardial infarction. N Engl J Med. 1977 Oct 6;297(14):750–757. doi: 10.1056/NEJM197710062971404. [DOI] [PubMed] [Google Scholar]
  13. Waleffe A., Mary-Rabine L., de Rijbel R., Soyeur D., Legrand V., Kulbertus H. E. Electrophysiological effects of propafenone studied with programmed electrical stimulation of the heart in patients with recurrent paroxysmal supraventricular tachycardia. Eur Heart J. 1981 Aug;2(4):345–352. doi: 10.1093/oxfordjournals.eurheartj.a061215. [DOI] [PubMed] [Google Scholar]

Articles from Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES